End-to-end FDA premarket cybersecurity for prescription DTx - mobile/web app, cloud, prescription auth, and SaMD-aligned threat model and SBOM.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Digital therapeutics submissions are often the first time a software-only company encounters FDA's premarket cybersecurity expectations, and the package looks different from a hardware device: there's no firmware, the entire product is the app and the cloud, and the threat model has to focus on prescription integrity, content integrity, and the patient-clinician trust model. Our full-service premarket package for DTx delivers an SPDF, SaMD-tuned threat model, SBOM, pen testing, and architecture views aligned to the FDA 2026 final premarket guidance and to the SaMD-specific reviewer expectations.
We build the threat model around the prescription pathway (who can issue / fulfill / modify a prescription, and what controls prevent unauthorized intervention), the content-delivery pathway (can a tampered intervention reach a patient?), and the data-collection pathway (PHI handling, sharing with clinicians, research-data export). Mobile app and cloud SBOMs are generated from the build pipeline with VEX. Pen testing exercises the mobile app under instrumented runtime, the cloud APIs for IDOR and cross-tenant leakage (DTx is multi-tenant by default), and the prescription/auth flow for replay and impersonation. Security architecture views include both the global system view and the multi-patient harm view - because DTx, like RPM, serves many patients from one cloud. Package is eSTAR-ready.
The digital therapeutics system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this full-service fda premarket cybersecurity.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Four phases, fixed fee, scoped to digital therapeutics architecture from kickoff onward.
Existing artifacts mapped against Section 524B(b) and the Feb 2026 guidance; gaps flagged in one document.
Threat model, SBOM + VEX, SPDF, architecture views, cybersecurity risk assessment, and labeling produced or upgraded as needed.
Independent pen test executed and findings closed before lock so the report ships clean inside the submission.
Every artifact delivered in the exact attachment format reviewers expect; we stay on call through the review cycle.
The patterns we hit in this segment, this service, again and again.
App posts 'prescriber-approved' flag; cloud accepts it. Reviewer asks how that's enforced server-side; gap surfaces.
Tampered or substituted intervention content not in threat model. Reviewer asks what stops it.
Multi-tenant cloud with shared infra; isolation controls described in code, not evidenced in submission.
Pen test treats app as a black-box web client. DTx app should be tested under instrumentation; gap noted.
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
The same deliverables the parent Full-Service FDA Premarket Cybersecurity service ships with - tuned to your digital therapeutics architecture.
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
The Digital Therapeutics baseline, plus the call-outs that matter for full-service fda premarket cybersecurity in this segment.
Software-only products still need full SPDF + threat model + SBOM + pen test + architecture views. No 'lite' version for DTx.
Threat-model framework reviewers will reference for SaMD.
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
The questions buyers in this segment actually ask before scoping a full-service fda premarket cybersecurity engagement.
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
PreSTAR vs eSTAR explained: PreSTAR is the voluntary FDA template for Q-Submissions, eSTAR is required for 510(k) and De Novo. How cybersecurity carries across.
Medical device cybersecurity at each study stage: rodent, large animal, primate, and human trials, and what the FDA expects before your IDE and marketing submission.
What a medical device security advisor does after FDA clearance: keeping the threat model and SBOM current, rating vulnerabilities, and answering hospitals.
Teams in this segment commonly bundle these alongside full-service fda premarket cybersecurity.
A 30-minute call with a senior engineer who has done this in digital therapeutics before - not a sales rep.
